Webinars and Commercial Conversations — Register Now
Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Abbott
| Company | Abbott |
|---|---|
| Name of instrument | Alinity ci-series |
| Contact | US Marketing Core Diagnostics |
| City, State | Abbott Park, IL |
| Phone | 800-323-9100 |
| Website | corelaboratory.abbott |
| Type of instrument | combination chemistry/immunoassay |
| List price/First year sold in U.S. | —/2018 |
| Targeted hospital bed size/Targeted test volume | all/— |
| Company manufactures instrument | yes |
| Other models in this family of analyzers | — |
| No. of units in clinical use in U.S./Outside U.S. (countries) | ~3,625/~16,600 (154 countries) |
| Dimensions (H × W × D)/Instrument footprint | 4.4 × 3.9 × 3.84 for standalone module; up to 4.4 × 11.81 × 3.84 for 4-module system/14.98–45.31 sq. ft. for 1- to 4-module system |
| Weight empty/Weight fully loaded | chem: 1,556 lbs.; immuno: 1,371 lbs./— |
| No. of different measured assays onboard simultaneously | chem: up to 280 (up to 280 can be run and calibrated at one time); immuno: up to 188 (up to 188 can be run and calibrated at one time) |
| No. of user-definable (open chemistry) channels | 10 (10 can be active simultaneously) |
| Test throughput per hour/Assay run time | up to 5,400 for Alinity c 4-module system; up to 800 for Alinity i 4-module system/depends on configuration |
| No. of direct ion-selective electrode channels | 3 |
| Detection methods | photometry, potentiometry |
| Stat time until completion/specimen throughput for Ion-selective electrode | — |
| Stat time until completion/specimen throughput for Ion-selective electrode basic metabolic panel | — |
| Stat time until completion/specimen throughput for Ion-selective electrode complete metabolic panel | — |
| Typical time delay from ordering stat test until aspiration of sample | < 30 sec. |
| Fully automated microplate immunoassay system | no |
| Methodologies supported | chemiluminescence |
| Separation methodologies | magnetic particle |
| Stat time until completion of a ß-hCG test | — |
| Stat time until completion of a cTn test | — |
| • Typical time delay from test order to aspiration of sample | — |
| Reagents refrigerated onboard/Reagents ready to use | yes (2°–10°C [chemistry], 2°–12°C [immunoassay])/yes |
| Reagent lot tracking/Reagent inventory | yes/yes |
| Reagent form/Reagents barcoded | liquid chemistry (open reagent system)/yes |
| Separate reagent pack for each specimen/for each test run | no/no |
| Walkaway capability/Walkaway duration | yes/240 min. or up to 600 specimens (150 specimens per module) |
| Design of sample-handling system | 6-position rack |
| Uses washable cuvettes/Uses disposable cuvettes | chem: yes/immuno: yes (can store up to 1,000 cuvettes) |
| Min.–max. sample volume that can be aspirated at one time | 1.5–35 µL (chemistry), 2–200 µL (immunoassay) |
| Min. reaction volume/Min. specimen volume/Min. dead volume | 80 µL/assay dependent/50 µL |
| Dedicated pediatric sample cup | no |
| Primary tube sampling | yes |
| Accommodates most standard tube sizes/Accepts nonstandard tube sizes | yes/yes (10–16.1 × 72–102 mm) |
| Pierces caps on primary tubes | no |
| Protects against probe collision | yes |
| Detects clots/liquid level/short sample | yes/yes/yes |
| Detection or quantitation for hemolysis, icterus, lipemia, clots | detection for hemolysis, icterus, lipemia, clots; quantitation for hemolysis, icterus, lipemia |
| Dilutes patient samples onboard/Susceptibility to carryover | yes/≤ 0.1 parts per million |
| Automatic rerun capability | yes |
| Sample volume can be diluted to rerun out-of-linear-range high results | yes |
| Sample volume can be concentrated to rerun out-of-linear-range low results | — |
| Autocalibration/Multipoint calibration supported | yes (calibrants are stored onboard)/yes |
| Typical calibration frequency for ISE/therapeutic drugs/drugs of abuse/general chemistries/immunoassays | 1 day/new lot or 7–45 days/new lot or 13 days/new lot or 30 days/new lot or 30 days |
| Automatic programmable start/Automatic programmable shutdown | —/no |
| Onboard real-time QC/Onboard software capability to review QC | yes/yes |
| Supports multiple QC lot numbers per analyte | yes |
| Waste management | automated collection onboard instrument or direct to drain |
| Sample barcode-reading capability/Autodiscrimination | yes (Interleaved 2 of 5, Codabar, Code 39, Code 128)/yes |
| Lab can control analyzer from remote computer | yes |
| Instrument can diagnose its own malfunctions | yes (operator intervention required to order parts) |
| System malfunctions can be diagnosed via remote monitoring | yes |
| UPS backup power supply | yes |
| Data-management capability/LIS or EHR systems interfaced | onboard/— |
| LIS interface provided/Bidirectional interface capability | no/yes (broadcast download and host query) |
| Modem servicing provided/Service engineer on-site response time | —/based on contract |
| Mean time between failures | — (displays error codes for troubleshooting) |
| Average scheduled maintenance time by lab personnel | daily: 0 (chem and immuno); weekly: 30 min. (chem), 16 min. (immuno); monthly: 2 min. (chem), 0 (immuno) |
| Maintenance records kept onboard for user/vendor | some records (includes audit trail of who replaced parts)/no |
| Maintenance training demonstration module onboard | yes |
| Training included with purchase/Avg. time for basic user training | yes (2 training slots)/12 hrs. (at customer site) |
| Advanced operator training/Extra charge for follow-up or advanced training | yes (at customer or vendor site)/yes |
| Warranty provided/Cost of annual service contract (24 h/7 d) | yes (varies by contract)/varies by contract |
| Distinguishing features (supplied by company) | compact, flexible, and scalable up to four modules and 14 configurations; harmonized family of systems across key lab disciplines leading to easier cross-training for lab staff; broad menu of high-quality assays aligned to CLSI guidelines |